Diabetes · Mechanism
A glucose-regulating mechanism confirmed in humans — that explains none of the inherited risk
Save this development or follow its topic to track what changes.
Short answer
TXNIP responds to insulin and glucose and can inhibit glucose uptake, but its genetic variation did not explain inherited type 2 diabetes risk.
What happened
Parikh and colleagues combined euglycaemic-hyperinsulinaemic clamps, muscle gene expression, genetics and cellular work. TXNIP, along with BCL6, was consistently repressed by insulin. It is reciprocally regulated by insulin and glucose, elevated in type 2 diabetes and prediabetes, inversely related to insulin-stimulated glucose uptake in people without diabetes, and capable of inhibiting glucose uptake when raised. Genetic variation in TXNIP did not account for inherited risk of the disease.
Why it matters
Mechanism and heritability are separate questions that the word 'gene' blurs. A gene can sit squarely in the causal physiology of a disease while contributing nothing measurable to who inherits it — which is why a mechanistic result and a genome-wide association result can both be right about the same gene and disagree about its importance.
Evidence
- Study type
- Human physiology combining hyperinsulinaemic clamps, muscle expression profiling, genetic association and cellular work
- Sample
- Clamp and muscle-biopsy participants with accompanying genetic and in vitro experiments
- Journal
- PLoS Medicine · peer reviewed
- Replication
- Not assessed in this corpus
- Limitations
- Mechanistic physiology rather than a trial. TXNIP variation did not explain inherited risk here, and no intervention on TXNIP was tested in people.
What this connects to
Sources
The one study this explanation is built from, by the role each plays. Every source links to PaperFren’s explanation of it and to the original paper.
Primary study
- How does TXNIP control muscle glucose uptake?
Human studies show TXNIP is repressed by insulin, induced by glucose, elevated in dysglycaemia, and can inhibit peripheral glucose uptake.
What it does not showLimitations
TXNIP genetic variation did not explain inherited T2DM risk here; this is mechanistic physiology, not a drug trial.
PaperFren explanationStudy with cards and a quizOriginal paper (DOI)cc by
Before
Candidate genes for type 2 diabetes were evaluated primarily by whether their variants associated with disease risk in genetic studies.
Now
A gene can be central to the physiology and absent from the heritability. This is mechanistic human physiology, not a trial: nothing here shows that lowering TXNIP improves glycaemic outcomes.